Patients with locally advanced gastric cancers saw complete response rates of 18.3% from camrelizumab and rivoceranib plus ...
CAN-2409 resulted in disease-free survival improvements for patients with high-risk, localized prostate cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback